Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.
about
Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.Prostate cancer as a model for tumour immunotherapy.Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic modelRegulatory considerations for clinical development of cancer vaccinesSequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.TGF-beta signalling and immunity in prostate tumourigenesis.Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Increased pressure stimulates aberrant dendritic cell maturation.Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression
P2860
Q33756646-BD04535E-DAE8-4349-8B46-F4229BE9AED9Q33837085-80864B84-23A2-415C-99B9-2B9A5EFE45B5Q34856691-DD207162-7DFD-484D-82B3-EC68CB8D09EEQ34856875-3434C1FC-D2D0-4DA0-A024-9B6148CEC5B0Q35641792-1347DA4B-F496-4061-8353-5D5B35D56407Q35886454-7A471683-E0DA-4574-9D86-7B0B9E921659Q36884975-B80331E5-6E39-48E9-8C8A-E7C4C66ABB8AQ36982946-49CA1265-EA85-4B3D-AFBE-67566495C770Q36983599-B1E48DC6-6AFA-4A48-8547-F2A581A140A8Q37670250-CD9B706B-6155-4CA6-A219-81154D23EB2AQ38088635-9D6A699A-9672-4D33-AA5D-0E61F9E56E68Q38779877-9329143E-ABD6-4324-9C79-B43902214304Q40030490-A9DD5384-A574-45F0-AAA1-19C49FF6530FQ40080152-52D983FA-CC3B-429E-B004-66CA4264ABC1Q43248975-EA384FC5-9824-4B0E-84E9-49E70F141FB7Q56797372-5FFE4D74-F8EA-4791-95E9-4DEA9AECF359
P2860
Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dendritic cells program non-im ...... ges of prostate tumorigenesis.
@ast
Dendritic cells program non-im ...... ges of prostate tumorigenesis.
@en
type
label
Dendritic cells program non-im ...... ges of prostate tumorigenesis.
@ast
Dendritic cells program non-im ...... ges of prostate tumorigenesis.
@en
prefLabel
Dendritic cells program non-im ...... ges of prostate tumorigenesis.
@ast
Dendritic cells program non-im ...... ges of prostate tumorigenesis.
@en
P2093
P2860
P356
P1433
P1476
Dendritic cells program non-im ...... ages of prostate tumorigenesis
@en
P2093
Aaron M Slaiby
Adam J Adler
Adam T Hagymasi
Marianne A Mihalyo
P2860
P304
P356
10.1002/PROS.20549
P50
P577
2007-04-01T00:00:00Z